Advocacy intelligence hub — real-time data for patient organizations
Rebyota: FDA approved
prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Rebyota
(fecal microbiota, live - jslm)Orphan drugFerring Pharmaceuticals, Inc.
12.1 Mechanism of Action The mechanism of action of REBYOTA has not been established.